Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.

In addition, overexpression of TP53 improved the sensitivity to sorafenib, although the result did not reach statistical significance (Figure 2 A).

also in 111,027 other papers